Ningbo HicRen Biotechnology Co., Ltd, a China-based robotics-driven minimally invasive orthopedics platform, announced the completion of a pre-Series C financing round of RMB100 million ($14.8 million). The round was led by Haichuang Group and Ningbo Qianwan Holding Group, with proceeds allocated to R&D, regulatory filings, and commercialization of orthopedic surgical robots and minimally invasive consumables.
Company Background
Founded in 2011, HicRen is the first domestic firm to gain market approvals for angled vertebroplasty surgery products in China and the EU. Its portfolio includes orthopedic surgical robots, vertebroplasty tools, spinal implants, bone repair materials, sports medicine products, and active equipment.
Strategic Partnerships
In November 2021, Austria’s Interventional Systems partnered with HicRen to enter China’s orthopedic microsurgery robot market. HicRen subsequently established a Shanghai entity to expand its presence.-Fineline Info & Tech
